Therapeutic drug monitoring of enteric-coated mycophenolate sodium by limited sampling strategies is associated with a high rate of failure

Conclusions
The risk of therapeutic drug monitoring failure with EC-MPS is >30% during the first 6 months of renal transplantation. Delayed pharmacokinetics was the main reason. In contrast, the risk of therapeutic drug monitoring failure was substantially lower with MMF.

Source: CKJ: Clinical Kidney Journal - March 15, 2016 Category: Urology & Nephrology Authors: Hougardy, J.-M., Maufort, L., Cotton, F., Coussement, J., Mikhalski, D., Wissing, K. M., Le Moine, A., Broeders, N., Abramowicz, D. Tags: TRANSPLANTATION Source Type: research